Title: The Impact of KRAS Mutations on Risk of Venous Thromboembolism Recurrence in
Patients with Metastatic Colorectal Cancer
Version: 2 Date: 24 Feb 2025
Reviewer's report:
This study investigated the relationship between KRAS mutations and the risk of venous
thromboembolism (VTE) recurrence in 2195 metastatic colorectal cancer patients with
established cancer-associated thrombosis (CAT). The study aimed to assess the predictive value
of seven KRAS mutation subtypes for VTE recurrence and to evaluate how incorporating these
mutations affects two existing VTE risk scores (the Khorana and Ottawa scores). The results
showed that the KRAS mutations G12C, G12A, and G13D were significantly associated with
a higher risk of recurrent VTE. Incorporating these mutations into the original Khorana and
Ottawa scores improved their predictive accuracy. The authors conclude that specific KRAS
mutations (G12C, G12A, and G13D) are linked to an increased risk of recurrent VTE, and
incorporating them into existing risk scores may enhance the ability to predict VTE recurrence
in metastatic colorectal cancer patients.
The study is of interest and warrants publication pending the following:
- the authors should discuss how race and ethnicity can impact the risk of thromboembolism in
cancer patients and  the possible limitations in applying their findings to different ethnic groups,
if any.
Title: The Impact of KRAS Mutations on Risk of Venous Thromboembolism Recurrence in
Patients with Metastatic Colorectal Cancer
Version: 2 Date: 24 Feb 2025
Reviewer's report:
This study investigated the relationship between KRAS mutations and the risk of venous
thromboembolism (VTE) recurrence in 2195 metastatic colorectal cancer patients with
established cancer-associated thrombosis (CAT). The study aimed to assess the predictive value
of seven KRAS mutation subtypes for VTE recurrence and to evaluate how incorporating these
mutations affects two existing VTE risk scores (the Khorana and Ottawa scores). The results
showed that the KRAS mutations G12C, G12A, and G13D were significantly associated with
a higher risk of recurrent VTE. Incorporating these mutations into the original Khorana and
Ottawa scores improved their predictive accuracy. The authors conclude that specific KRAS
mutations (G12C, G12A, and G13D) are linked to an increased risk of recurrent VTE, and
incorporating them into existing risk scores may enhance the ability to predict VTE recurrence
in metastatic colorectal cancer patients.
The study is of interest and warrants publication pending the following:
- the authors should discuss how race and ethnicity can impact the risk of thromboembolism in
cancer patients and  the possible limitations in applying their findings to different ethnic groups,
if any.
Please review this paper.
user
Title: The Impact of KRAS Mutations on Risk of Venous Thromboembolism Recurrence in
Patients with Metastatic Colorectal Cancer
Version: 2 Date: 24 Feb 2025
Reviewer's report:
This study investigated the relationship between KRAS mutations and the risk of venous
thromboembolism (VTE) recurrence in 2195 metastatic colorectal cancer patients with
established cancer-associated thrombosis (CAT). The study aimed to assess the predictive value
of seven KRAS mutation subtypes for VTE recurrence and to evaluate how incorporating these
mutations affects two existing VTE risk scores (the Khorana and Ottawa scores). The results
showed that the KRAS mutations G12C, G12A, and G13D were significantly associated with
a higher risk of recurrent VTE. Incorporating these mutations into the original Khorana and
Ottawa scores improved their predictive accuracy. The authors conclude that specific KRAS
mutations (G12C, G12A, and G13D) are linked to an increased risk of recurrent VTE, and
incorporating them into existing risk scores may enhance the ability to predict VTE recurrence
in metastatic colorectal cancer patients.
The study is of interest and warrants publication pending the following:
- the authors should discuss how race and ethnicity can impact the risk of thromboembolism in
cancer patients and  the possible limitations in applying their findings to different ethnic groups,
if any.
assistant